Content overview: “FDA Advisory Panels: Nearly 40% of Meetings Feature Patient Reps with Industry Ties, Study”. New research reveals that almost 40% of FDA advisory committee meetings over the past two decades included at least one patient or consumer representative with active ties to an advocacy group, raising fresh questions about influence on drug approval decisions. The study, which analyzed meetings from 2000 to 2021, found that these representatives often had financial or organizational connections to pharmaceutical companies or patient groups funded by industry. This pattern persisted even as the FDA has worked to increase patient voices in regulatory processes.
Experts argue that such ties could skew deliberations, especially when committees weigh the benefits and risks of new therapies. The findings come amid broader scrutiny of conflicts of interest on federal advisory panels, with some lawmakers calling for stricter disclosure rules. This listing links straight to the original page, where the content is available in full.